New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
07:34 EDTCPHDCepheid 2013 sales of CT/NG estimated $15M-$20M at William Blair
William Blair expects solid initial demand for Cepheid's just approved Xpert CT/NG from existing Xpert customers and projects 2013 sales between $15M-$20M on a worldwide basis. However, William Blair says it is not sure if Cepheid will be able to ship enough product to meet initial demand as it provided no update on the recent manufacturing issues. The firm keeps an Outperform rating on the stock.
News For CPHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:26 EDTCPHDCepheid price target raised to $67 from $58 at JMP Securities
Subscribe for More Information
April 23, 2015
16:27 EDTCPHDCepheid sees FY15 adjusted EPS 25c-29c, may not compare to consensus (52c)
Subscribe for More Information
16:26 EDTCPHDCepheid reports Q1 adjusted EPS 17c, may not compare to consensus (16c)
Subscribe for More Information
April 16, 2015
07:06 EDTCPHDCepheid's Xpert HIV-1 Qual for HIV approved in Europe
Subscribe for More Information
April 15, 2015
07:02 EDTCPHDCepheid announces European approval of Xpert HCV Viral Load
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use